Video
Dr. Kamran on including immunotherapy in bladder-preservation therapy
Author(s):
“The NRG SWOG 1806 trial is a phase 3 trial randomizing patients to standard trimodality therapy or trimodality therapy plus atezolizumab,” says Sophia Kamran, MD.
Video Player is loading.
Sophia Kamran, MD, discusses the potential of adding immune-checkpoint inhibitors, such as the PD-L1 inhibitor atezolizumab (Tecentriq) to bladder-preservation, or “trimodal,” therapy for patients with bladder cancer. Kamran is a radiation oncologist at Massachusetts General Hospital and assistant professor of Radiation Oncology at Harvard Medical School.
Related Videos
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Sima Porten, MD, on gene-environment interactions in bladder cancer development
How rBCG EAP could open up access for Anktiva in bladder cancer
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Related Content
